Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025-2031: Yescarta from Gilead Sciences and Zolgensma from Novartis Generated $1.5 Billion and $1.2 Billion in 2024 Sales [Yahoo! Finance]
Gilead Sciences (NASDAQ:GILD) had its price target lowered by analysts at Royal Bank Of Canada from $105.00 to $100.00. They now have a "sector perform" rating on the stock.
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $110.00 to $115.00. They now have a "neutral" rating on the stock.
Hopping Mad Over Drug Company Product Hopping [Forbes]
Gilead Sciences (NASDAQ:GILD) had its "buy" rating reaffirmed by analysts at UBS Group AG.